NexCure, a Boston, MA-based provider of a platform that standardises protocols, automates care coordination, and reduces operational variability, has raised $19 million in a Series A funding round led by RA Capital Management.
The round also saw participation from Cencora Ventures and Oncology Ventures.
Read More:Levitate Raises $16M in Funding
The company plans to use the funds to expand its operations and continue developing its products.
NexCure combines specialised outpatient clinics with its own technology to support complex treatments such as CAR-T and other advanced therapies. The company brings these intensive treatments into outpatient settings, helping remove geographic, financial, and logistical barriers for patients. This approach improves access to care for patients while also supporting referring oncologists, health systems, payers, and therapy manufacturers that need reliable treatment locations.
The company was founded by Raven, the healthcare incubator of RA Capital Management, to address limited capacity and access to life-saving therapies. In the United States, only about 200 of the 6,100 hospitals—around 3%—currently provide CAR-T therapy.
“I have seen firsthand how cell therapy can help people with cancer and other diseases, and we are committed to overcoming the operational challenges that limit access to these treatments,” said Sophie Papa, Founder and Chief Medical Officer at NexCure. “NexCure is working to make complex therapies with high care and monitoring needs more accessible to the patients who need them.”
“Today, only a small number of patients who qualify for CAR-T therapy actually receive it, mainly because of where and how the treatment is provided,” said Paul Rothman, Venture Partner at Raven and Founder and Board Chair of NexCure. “As CAR-T therapy grows and expands beyond cancer to treat autoimmune and other diseases, NexCure plans to work with the healthcare ecosystem to increase access so more patients can receive advanced treatments in safe and effective settings closer to home.”
“CAR-T and other advanced cancer therapies are reaching a breakthrough, but the systems needed to deliver them have not kept up,” said Ben Freeberg, Founder and Managing Partner of Oncology Ventures. “We are excited to invest in NexCure as it addresses this challenge with a scalable outpatient clinic model that expands access, improves efficiency, and creates new ways to deliver advanced treatments safely.”
About NexCure
NexCure delivers complex therapies in community-based outpatient clinics, changing how CAR-T and other advanced treatments are provided and monitored. The company brings hospital-level care to scalable outpatient clinics designed for next-generation therapies. Its platform uses AI for patient selection, remote monitoring, and standardised clinical protocols to ensure patients receive safe, personalised, high-quality treatment.
Read More:Sierra Space Closes $550M Series C Funding Round
